AU2013205648B2 - Combination treatment - Google Patents

Combination treatment Download PDF

Info

Publication number
AU2013205648B2
AU2013205648B2 AU2013205648A AU2013205648A AU2013205648B2 AU 2013205648 B2 AU2013205648 B2 AU 2013205648B2 AU 2013205648 A AU2013205648 A AU 2013205648A AU 2013205648 A AU2013205648 A AU 2013205648A AU 2013205648 B2 AU2013205648 B2 AU 2013205648B2
Authority
AU
Australia
Prior art keywords
combination
azd5363
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013205648A
Other languages
English (en)
Other versions
AU2013205648A1 (en
Inventor
Barry Robert Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013205648(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to AU2013205648A priority Critical patent/AU2013205648B2/en
Publication of AU2013205648A1 publication Critical patent/AU2013205648A1/en
Application granted granted Critical
Publication of AU2013205648B2 publication Critical patent/AU2013205648B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013205648A 2011-11-30 2012-11-30 Combination treatment Active AU2013205648B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013205648A AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
US61/564,975 2011-11-30
AU2013205648A AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment
AU2012321110A AU2012321110B2 (en) 2011-11-30 2012-11-30 Combination treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2012321110A Division AU2012321110B2 (en) 2011-11-30 2012-11-30 Combination treatment

Publications (2)

Publication Number Publication Date
AU2013205648A1 AU2013205648A1 (en) 2013-06-13
AU2013205648B2 true AU2013205648B2 (en) 2015-02-05

Family

ID=47295082

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012321110A Active AU2012321110B2 (en) 2011-11-30 2012-11-30 Combination treatment
AU2013205648A Active AU2013205648B2 (en) 2011-11-30 2012-11-30 Combination treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2012321110A Active AU2012321110B2 (en) 2011-11-30 2012-11-30 Combination treatment

Country Status (26)

Country Link
US (2) US20140329786A1 (OSRAM)
EP (1) EP2785349B2 (OSRAM)
JP (1) JP6309454B2 (OSRAM)
KR (1) KR102035361B1 (OSRAM)
CN (1) CN103945849B (OSRAM)
AU (2) AU2012321110B2 (OSRAM)
CA (1) CA2856646C (OSRAM)
CY (1) CY1122624T1 (OSRAM)
DK (1) DK2785349T4 (OSRAM)
ES (1) ES2762250T5 (OSRAM)
FI (1) FI2785349T4 (OSRAM)
HR (1) HRP20191982T4 (OSRAM)
HU (1) HUE046667T2 (OSRAM)
IL (1) IL232530B (OSRAM)
LT (1) LT2785349T (OSRAM)
MX (1) MX367640B (OSRAM)
MY (1) MY175800A (OSRAM)
PH (1) PH12014500943A1 (OSRAM)
PL (1) PL2785349T5 (OSRAM)
PT (1) PT2785349T (OSRAM)
RS (1) RS59493B2 (OSRAM)
RU (1) RU2640485C2 (OSRAM)
SG (1) SG11201401471PA (OSRAM)
SI (1) SI2785349T2 (OSRAM)
SM (1) SMT201900708T1 (OSRAM)
WO (1) WO2013079964A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
ES2770308T3 (es) 2008-10-02 2020-07-01 Salix Pharmaceuticals Ltd Procedimientos de tratamiento de encefalopatía hepática
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
SG191724A1 (en) 2011-01-11 2013-08-30 Glaxosmithkline Llc Combination
JP2015503508A (ja) * 2011-12-22 2015-02-02 トーカイ ファーマシューティカルズ，インク． ＰＩ３Ｋ／ｍＴＯＲ阻害剤を使用する併用療法のための方法および組成物
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN105792825A (zh) * 2013-10-01 2016-07-20 诺华股份有限公司 组合
WO2015116696A1 (en) * 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3487497B1 (en) 2016-07-21 2021-09-08 Hadasit Medical Research Services and Development Ltd. Combinations comprising ar antagonists or inhibitors for use in treating glioblastoma
AU2017376704B2 (en) 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
CA3075095A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法
CA3131034A1 (en) 2019-03-06 2020-09-10 Matthew J. Sharp Abiraterone prodrugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066962A2 (en) * 2003-01-17 2004-08-12 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090163524A1 (en) * 2007-10-11 2009-06-25 Astrazeneca Ab Novel Protein Kinase B Inhibitors - 060
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (OSRAM) 1963-04-04 1900-01-01
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
WO1993020097A1 (en) 1992-03-31 1993-10-14 British Technology Group Ltd. 17-substituted steroids useful in cancer treatment
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
CN1264381A (zh) 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
NZ525885A (en) 2000-12-01 2005-01-28 Osi Pharm Inc Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
UY27220A1 (es) 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
ES2262996T3 (es) 2002-01-07 2006-12-01 Eisai Co., Ltd. Deazapurinas y sus usos.
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
UA81628C2 (uk) 2002-05-17 2008-01-25 Авентіс Фарма С.А. Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози
EP2508204B1 (en) 2002-06-26 2014-09-24 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
EP1567495A4 (en) 2002-11-08 2007-10-31 Harvard College SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS
WO2004050656A1 (ja) 2002-12-04 2004-06-17 Eisai Co., Ltd. １，３−ジヒドロ−イミダゾール縮合環化合物
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
JP2006519846A (ja) 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
EP1615926A1 (en) 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
CN101128195A (zh) * 2005-02-23 2008-02-20 阿斯利康(瑞典)有限公司 用于递送增加的稳态血浆水平的比卡鲁胺
RS53967B1 (sr) 2005-05-13 2015-08-31 The Regents Of The University Of California Diaril hidantoin jedinjenja kao antagonisti receptora androgena za lečenje raka
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
US20100016340A1 (en) 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
CA2673472A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
CN102388048B (zh) * 2009-02-10 2014-07-30 阿斯利康(瑞典)有限公司 三唑并[4，3-b]哒嗪衍生物及其用于前列腺癌的用途
JP2013504531A (ja) * 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
JP6042802B2 (ja) * 2010-04-27 2016-12-14 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066962A2 (en) * 2003-01-17 2004-08-12 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20090163524A1 (en) * 2007-10-11 2009-06-25 Astrazeneca Ab Novel Protein Kinase B Inhibitors - 060
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SARTOR, O., ET AL, "Novel Therapeutic Strategies for Metastatic prostate Cancer in the Post- Docetaxel Setting". The Oncologist, November 2011, vol. 16, pages 1487-1497. First published in The Oncologist Express on November 2, 2011 *
THOMAS, C., ET AL, Urology, September 2011, vol. 78, suppl. 3, abstract UP-02.098 *

Also Published As

Publication number Publication date
CN103945849A (zh) 2014-07-23
US20160151373A1 (en) 2016-06-02
SG11201401471PA (en) 2014-08-28
BR112014012261A2 (pt) 2017-06-13
EP2785349A1 (en) 2014-10-08
ES2762250T5 (es) 2023-01-05
AU2012321110A1 (en) 2013-06-20
MY175800A (en) 2020-07-09
HRP20191982T4 (hr) 2023-01-06
HUE046667T2 (hu) 2020-03-30
EP2785349B2 (en) 2022-11-09
PT2785349T (pt) 2019-12-11
RS59493B1 (sr) 2019-12-31
MX2014006547A (es) 2014-07-09
ES2762250T3 (es) 2020-05-22
US9737540B2 (en) 2017-08-22
DK2785349T3 (da) 2020-01-02
CA2856646C (en) 2020-01-14
RU2014119713A (ru) 2016-01-27
JP6309454B2 (ja) 2018-04-11
IL232530B (en) 2018-07-31
AU2013205648A1 (en) 2013-06-13
HK1202253A1 (en) 2015-09-25
NZ625611A (en) 2016-10-28
CA2856646A1 (en) 2013-06-06
PL2785349T5 (pl) 2023-01-30
AU2012321110B2 (en) 2014-10-23
RS59493B2 (sr) 2023-02-28
PL2785349T3 (pl) 2020-03-31
RU2640485C2 (ru) 2018-01-09
LT2785349T (lt) 2019-12-10
KR102035361B1 (ko) 2019-11-08
IL232530A0 (en) 2014-06-30
MX367640B (es) 2019-08-29
EP2785349B1 (en) 2019-10-16
CY1122624T1 (el) 2021-03-12
PH12014500943A1 (en) 2014-06-30
SI2785349T2 (sl) 2023-01-31
WO2013079964A1 (en) 2013-06-06
JP2015500225A (ja) 2015-01-05
HRP20191982T1 (hr) 2020-02-07
CN103945849B (zh) 2017-04-26
US20140329786A1 (en) 2014-11-06
SMT201900708T1 (it) 2020-01-14
DK2785349T4 (da) 2023-01-09
KR20140098799A (ko) 2014-08-08
SI2785349T1 (sl) 2019-12-31
FI2785349T4 (fi) 2023-02-09

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
CN108024541B (zh) 用于治疗癌症的方法
CN112773765A (zh) 治疗普拉德-威利综合征的方法
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
AU2021382148A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN115038447A (zh) 用于治疗癌症的组合疗法
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
TW202339726A (zh) 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179
NZ625611B2 (en) Combination treatment of cancer
HK1202253B (en) Combination treatment of cancer
EP4663187A1 (en) 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain
JP2024542831A (ja) Ｐｋｃ阻害剤及びｃ－ｍｅｔ阻害剤を含む併用療法
BR112014012261B1 (pt) Combinação e uso de (s)-4-amino-n-(1-(4-clorofenil)-3- hidroxipropil)-1-(7h-pirrolo [2,3-d] pirimidin-4-il)piperidina-4- carboxamida com um modulador da sinalização do receptor de androgênio
US20190160054A1 (en) Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DAVIES, BARRY ROBERT

FGA Letters patent sealed or granted (standard patent)